Hauttumore | ICD10: C43, C44, D03, D04
Sie befinden sich hier:
Bei allen Anfragen zu den Studien nehmen Sie bitte Kontakt mit der Cancer Hotline des CCCC auf.
Studien offen zur Rekrutierung
ADMEC-O (CA184-205)137 KB
Prospective Randomized Trial of an Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma (MCC) With 3 mg/kg BW Ipilimumab (Yervoy®) Every 3 Weeks for 12 Weeks Versus Observation
AliCe75 KB
Einarmige, offene, multizentrische Phase II Studie zur Untersuchung der klinischen Aktivität und Sicherheit von Avelumab in Kombination mit Cetuximab bei Studienteilnehmern mit nicht reserzierbarem Plattenepithelkarzinom im Stadium III oder IV.
COMBI-r266 KB
Beobachtungsstudie zu Sicherheit und Effizienz von Dabrafenib und Trametinib im klinischen Alltag (COMBI-r)
CureVac (CV-8102-008)98 KB
Phase I Study of Intratumoral CV8102 in Patients With Advanced Melanoma, Squamous Cell Carcinoma of the Skin, Squamous Cell Carcinoma of the Head and Neck, or Adenoid Cystic Carcinoma
FUSI-Projekt (PDL1-Studie)Expression of PDL1 and other relevant immune-checkpoints on CTCs and matched tissues in patients with metastatic melanoma
ILLUMINATE-301 (2125-MEL-301)A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With AntiPD1 Refractory Melanoma (ILLUMINATE-301)
IMCgp100-201106 KB
A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination with Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients with Advanced Melanoma
R2810-ONC-1540 (Regeneron)143 KB
A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD1), in Patients With Advanced Cutaneous Squamous Cell Carcinoma
RESMAIN152 KB
A Multicentre, Double Blind, Randomised, Placebo-controlled, Phase II Trial to Evaluate Resminostat for Maintenance Treatment of Patients With Advanced Stage (Stage IIB-IVB) Mycosis Fungoides (MF) or Sézary Syndrome (SS) That Have Achieved Disease Control With Systemic Therapy - the RESMAIN Study
TREAT20plusValidation of the virtual patient to optimise individual therapy for patients with metastatic melanoma